This article is a collaboration between ľֱ and:
NEW ORLEANS -- When the FDA says consider alternatives, as it did in the case of paclitaxel-based stents and balloons for use in peripheral arteries in an , you've got to listen -- even if you aren't quite convinced by the evidence.
That's what leading interventional cardiologists told ľֱ here at the American College of Cardiology meeting.
In this video, you'll hear from: Ajay Kirtane, MD, of Columbia University Medical Center/New York-Presbyterian Hospital in New York City, Roxana Mehran, MD, of The Mount Sinai Hospital in New York City, and E. Magnus Ohman, MD, of Duke University Medical Center in Durham, North Carolina.